A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell...

Full description

Bibliographic Details
Main Authors: Riccardo Turrini, Anna Merlo, Debora Martorelli, Damiana Antonia Faè, Roberta Sommaggio, Isabella Monia Montagner, Vito Barbieri, Oriano Marin, Paola Zanovello, Riccardo Dolcetti, Antonio Rosato
Format: Article
Language:English
Published: Taylor & Francis Group 2017-04-01
Series:OncoImmunology
Subjects:
adcc
barf1
cdc
epstein–barr virus
immunotherapy
monoclonal antibody
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1304338

Internet

http://dx.doi.org/10.1080/2162402X.2017.1304338

Similar Items